197 related articles for article (PubMed ID: 22849661)
1. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.
Accolla RS; Tosi G
J Transl Med; 2012 Jul; 10():154. PubMed ID: 22849661
[TBL] [Abstract][Full Text] [Related]
2. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
Wang RF
Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
[TBL] [Abstract][Full Text] [Related]
3. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
4. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
6. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
7. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
Wang RF
Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
[TBL] [Abstract][Full Text] [Related]
8. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
9. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
Wang RF
Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
11. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
13. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
14. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
15. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
16. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
18. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
19. Major Histocompatibility Complex Class II-Restricted, CD4
Ledbetter L; Cherla R; Chambers C; Zhang Y; Mitchell WJ; Zhang G
Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31792078
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
